Association of the KDIGO Risk Classification with the Prevalence of Heart Failure in Patients with Type 2 Diabetes

被引:4
作者
Gimeno-Orna, Jose Antonio [1 ]
Rodriguez-Padial, Luis [2 ]
Anguita-Sanchez, Manuel [3 ]
Barrios, Vivencio [4 ]
Muniz, Javier [5 ,6 ]
Perez, Antonio [7 ]
机构
[1] Hosp Clin Univ Lozano Blesa, Endocrinol & Nutr Serv, Zaragoza 50009, Spain
[2] Complejo Hosp Toledo, Cardiol Serv, Toledo 45004, Spain
[3] Univ Cordoba, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed IMIBIC, Cardiol Serv, Cordoba 14004, Spain
[4] Hosp Universitario Ramon y Cajal, Cardiol Serv, Madrid 28034, Spain
[5] Coruna Univ, Cardiovasc Res Grp, Hlth Sci Dept, La Coruna, Spain
[6] CIBERCV, Biomed Res Inst A Coruna INIBIC, La Coruna, Spain
[7] Univ Autonoma Barcelona, CIBER Diabet & Enfermedades Metabol CIBERDEM, Hosp Santa Creu & St Pau, Endocrinol & Nutr Serv & Res Inst IIB St Pau, Barcelona 08023, Spain
关键词
type; 2; diabetes; cardiovascular disease; heart failure; KDIGO risk category; CARDIOVASCULAR OUTCOMES; DISEASE; HYPERGLYCEMIA; METAANALYSIS; INSIGHTS; NEED;
D O I
10.3390/jcm10204634
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objectives of this study were to determine the main characteristics associated with the presence of heart failure (HF) in patients with type 2 diabetes (T2DM), and specifically to assess the association of the risk classification proposed by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines with HF. The DIABET-IC study is a multicentre, observational, prospective and analytical study in T2DM patients recruited in Spanish hospitals. This work, which features a cross-sectional design, has been conducted with the data obtained at the inclusion visit. The main dependent variable analysed was the presence of HF. The predictive variables evaluated were the demography, clinic, laboratory testing (including natriuretic peptides) and echocardiography. Patients were classified according to the number of vascular territories with atherosclerotic involvement and the KDIGO risk category. Multivariate logistic regression models were performed to determine the risk posed by the various baseline variables to present HF at the time of study inclusion. The study included 1517 patients from 58 hospitals, with a mean age of 67.3 (standard deviation (SD): 10) years, out of which 33% were women. The mean DM duration was 14 (SD: 11) years. The prevalence of HF was 37%. In a multivariate analysis, the independent predictors of HF were increased age (odds ratio (OR) per 1 year = 1.02; p = 0.006), decreased systolic blood pressure (OR per 1 mmHg = 0.98; p < 0.001), decreased haemoglobin (OR per 1 g/dL = 0.86; p < 0.001), the presence of obstructive sleep apnoea (OR = 1.61; p = 0.006), the absence of hepatic steatosis (OR = 0.59; p = 0.016), the severity of atherosclerotic involvement (OR 1 territory = 1.38 and OR > 1 territory = 2.39; p = 0.02 and p < 0.001 respectively) and the KDIGO risk classification (high-risk OR = 2.46 and very high-risk OR = 3.39; p < 0.001 for both). The KDIGO risk classification is useful to screen for the presence of HF in T2DM patients. Therefore, we believe that it is necessary to carry out a systematic screening for HF in the high- and very high-risk KDIGO categories.
引用
收藏
页数:12
相关论文
共 29 条
[2]  
American Diabetes Association, 2020, DIABETES CARE, V44, P150
[3]   Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications [J].
Bell, David S. H. ;
Goncalves, Edison .
DIABETES OBESITY & METABOLISM, 2019, 21 (06) :1277-1290
[4]   The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis [J].
Berry, C. ;
Doughty, R. N. ;
Granger, C. ;
Kober, L. ;
Massie, B. ;
McAlister, F. ;
McMurray, J. ;
Pocock, S. ;
Poppe, K. ;
Swedberg, K. ;
Somaratne, J. ;
Whalley, G. A. ;
Ahmed, A. ;
Andersson, B. ;
Bayes-Genis, A. ;
Berry, C. ;
Cowie, M. ;
Cubbon, R. ;
Doughty, R. N. ;
Ezekowitz, J. ;
Gonzalez-Juanatey, J. ;
Gorini, M. ;
Gotsman, I. ;
Grigorian-Shamagian, L. ;
Guazzi, M. ;
Kearney, M. ;
Kober, L. ;
Komajda, M. ;
di Lenarda, A. ;
Lenzen, M. ;
Lucci, D. ;
Macin, S. ;
Madsen, B. ;
Maggioni, A. ;
Martinez-Selles, M. ;
McAlister, F. ;
Oliva, F. ;
Poppe, K. ;
Rich, M. ;
Richards, M. ;
Senni, M. ;
Squire, I. ;
Taffet, G. ;
Tarantini, L. ;
Tribouilloy, C. ;
Troughton, R. ;
Tsutsui, H. ;
Whalley, G. A. ;
Doughty, R. N. ;
Earle, N. .
EUROPEAN HEART JOURNAL, 2012, 33 (14) :1750-1757
[5]   Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58 [J].
Bonaca, Marc P. ;
Wiviott, Stephen D. ;
Zelniker, Thomas A. ;
Mosenzon, Ofri ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Goodrich, Erica L. ;
De Mendonca Furtado, Remo Holanda ;
Wilding, John P. H. ;
Cahn, Avivit ;
Gause-Nilsson, Ingrid A. M. ;
Johanson, Per ;
Fredriksson, Martin ;
Johansson, Peter A. ;
Langkilde, Anna Maria ;
Raz, Itamar ;
Sabatine, Marc S. .
CIRCULATION, 2020, 142 (08) :734-747
[6]   Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].
Bonaca, Marc P. ;
Nault, Patrice ;
Giugliano, Robert P. ;
Keech, Anthony C. ;
Pineda, Armando Lira ;
Kanevsky, Estella ;
Kuder, Julia ;
Murphy, Sabina A. ;
Jukema, J. Wouter ;
Lewis, Basil S. ;
Tokgozoglu, Lale ;
Somaratne, Ransi ;
Sever, Peter S. ;
Pedersen, Terje R. ;
Sabatine, Marc S. .
CIRCULATION, 2018, 137 (04) :338-350
[7]   2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J].
Buse, John B. ;
Wexler, Deborah J. ;
Tsapas, Apostolos ;
Rossing, Peter ;
Mingrone, Geltrude ;
Mathieu, Chantal ;
D'Alessio, David A. ;
Davies, Melanie J. .
DIABETOLOGIA, 2020, 63 (02) :221-228
[8]   Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals [J].
Conrad, Nathalie ;
Judge, Andrew ;
Tran, Jenny ;
Mohseni, Hamid ;
Hedgecott, Deborah ;
Crespillo, Abel Perez ;
Allison, Moira ;
Hemingway, Harry ;
Cleland, John G. ;
McMurray, John J. V. ;
Rahimi, Kazem .
LANCET, 2018, 391 (10120) :572-580
[9]   2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD [J].
Cosentino, Francesco ;
Grant, Peter J. ;
Aboyans, Victor ;
Bailey, Clifford J. ;
Ceriello, Antonio ;
Delgado, Victoria ;
Federici, Massimo ;
Filippatos, Gerasimos ;
Grobbee, Diederick E. ;
Hansen, Tina Birgitte ;
Huikuri, Heikki, V ;
Johansson, Isabelle ;
Juni, Peter ;
Lettino, Maddalena ;
Marx, Nikolaus ;
Mellbin, Linda G. ;
Ostgren, Carl J. ;
Rocca, Bianca ;
Roffi, Marco ;
Sattar, Naveed ;
Seferovic, Petar M. ;
Sousa-Uva, Miguel ;
Valensi, Paul ;
Wheeler, David C. ;
Piepoli, Massimo Francesco ;
Birkeland, Kare, I ;
Adamopoulos, Stamatis ;
Ajjan, Ramzi ;
Avogaro, Angelo ;
Baigent, Colin ;
Brodmann, Marianne ;
Bueno, Hector ;
Ceconi, Claudio ;
Chioncel, Ovidiu ;
Coats, Andrew ;
Collet, Jean-Philippe ;
Collins, Peter ;
Cosyns, Bernard ;
Di Mario, Carlo ;
Fisher, Miles ;
Fitzsimons, Donna ;
Halvorsen, Sigrun ;
Hansen, Dominique ;
Hoes, Arno ;
Holt, Richard I. G. ;
Home, Philip ;
Katus, Hugo A. ;
Khunti, Kamlesh ;
Komajda, Michel ;
Lambrinou, Ekaterini .
EUROPEAN HEART JOURNAL, 2020, 41 (02) :255-323
[10]   Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science [J].
Drager, Luciano F. ;
McEvoy, R. Doug ;
Barbe, Ferran ;
Lorenzi-Filho, Geraldo ;
Redline, Susan .
CIRCULATION, 2017, 136 (19) :1840-1850